Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tonix Pharmaceuticals Holding (TNXP) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to 1005.08%.

  • Tonix Pharmaceuticals Holding's EBITDA Margin fell 4539100.0% to 1005.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 969.97%, marking a year-over-year increase of 2836900.0%. This contributed to the annual value of 1354.28% for FY2024, which is 1696600.0% up from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's EBITDA Margin stood at 1005.08%, which was down 4539100.0% from 1416.22% recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's EBITDA Margin's 5-year high stood at 551.17% during Q3 2024, with a 5-year trough of 3501.63% in Q2 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median EBITDA Margin value was 860.23% (recorded in 2024), while the average stood at 1143.86%.
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's EBITDA Margin showed a top increase of 20854100bps in 2025 and a maximum decrease of -4539100bps in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's EBITDA Margin (Quarter) stood at 723.18% in 2023, then dropped by -20bps to 870.64% in 2024, then fell by -15bps to 1005.08% in 2025.
  • Its EBITDA Margin was 1005.08% in Q3 2025, compared to 1416.22% in Q2 2025 and 660.93% in Q1 2025.